Show simple item record

5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

dc.contributor.authorRobert, C
dc.contributor.authorSchachter, J
dc.contributor.authorLong, GV
dc.contributor.authorArance, A
dc.contributor.authorGrob, JJ
dc.contributor.authorMortier, L
dc.contributor.authorDaud, A
dc.contributor.authorCarlino, MS
dc.contributor.authorMcNeil, C
dc.contributor.authorLotem, M
dc.contributor.authorLarkin, J
dc.contributor.authorLorigan, Paul C
dc.contributor.authorNeyns, B
dc.contributor.authorBlank, CU
dc.contributor.authorHamid, O
dc.contributor.authorPetrella, TM
dc.contributor.authorAnderson, J
dc.contributor.authorKrepler, C
dc.contributor.authorDiede, SJ
dc.contributor.authorRibas, A
dc.date.accessioned2019-11-19T16:01:02Z
dc.date.available2019-11-19T16:01:02Z
dc.date.issued2019en
dc.identifier.citationRobert C, Schachter J, Long G, Arance A, Grob J, Mortier L, et al. 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Cancer Res. 2019;79(13).en
dc.identifier.doi10.1158/1538-7445.AM2019-CT188en
dc.identifier.urihttp://hdl.handle.net/10541/622425
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1538-7445.AM2019-CT188en
dc.title5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGustave Roussy and Paris-Sud University, Villejuif,en
dc.identifier.journalCancer Researchen


This item appears in the following Collection(s)

Show simple item record